ArticleBMC infectious diseases2026
The predictive value of dyslipidemia for immune reconstitution outcome among HIV/AIDS patients after 24 months of viral suppression: a retrospective cohort study.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundDyslipidemia and poor immune reconstruction are mutually causal in HIV/AIDS patients. However, the predictive value of dyslipidemia for poor immune reconstruction remains a subject of debate. This study aims to assess the predictive value of specific blood lipid levels for poor immune reconstitution and changes in lipid profiles in HIV/AIDS patients.
methodsThe lipids level of 429 HIV/AIDS patients were measured, and patients were treated with antiretroviral therapy (ART) and followed up. The cohort was stratified into two groups based on immune function. Logistic regression analyses and receiver-operating characteristic (ROC) curves were employed to confirm the independent prognostic factors influencing immune reconstitution outcome. Sensitivity analyses were conducted across different subgroups.
resultsAt the conclusion of the follow-up period, the rate of overall immunological non-responders (INR) was 21.0%. The incidence of baseline dyslipidemia was higher in the INR group, with high-density lipoprotein cholesterol (HDL-C) being the primary contributor. Total cholesterol (TC), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-C) levels increased significantly after 24 months of viral suppression (P < 0.05), with a greater percentage increase in TC observed in the INR group. Logistic regression analysis revealed that HDL-C was a significant predictor of INR (OR = 0.247, 95% CI = 0.088–0.696, P = 0.008). Sensitivity analyses confirmed the robustness of the associations between HDL-C and poor immune reconstitution across various subgroups.
conclusionBaseline HDL-C level can serve as a prognostic marker for poor immune reconstitution in HIV/AIDS patients, and INR are more likely to exhibit elevated TC levels. Early lipid profile assessment could inform clinical management strategies, thereby improving better immune outcomes in this vulnerable population. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.